Pub Date : 2026-02-02DOI: 10.1001/jamanetworkopen.2025.56631
Anne J Maheux, Samir Akre-Bhide, Debra Boeldt, Jessica E Flannery, Zachary Richardson, Kaitlyn Burnell, Eva H Telzer, Scott H Kollins
Importance: As generative artificial intelligence (GenAI) tools become increasingly integrated into the daily lives of youth, it is critical to study their usage patterns and potential implications for mental health. While there is evidence of a rapid pace of adoption among adults, rates of GenAI use among youth remains largely undocumented.
Objective: To characterize GenAI application (app) usage among US youth, including adoption rates and time spent.
Design, setting, and participants: This cross-sectional study documented digital behavior of US youth extracted from a parental monitoring app. Participants were ages 4 to 17 years and were in families using a commercially available Aura app in the US. No identifying information was collected about the child except year of birth. Data were collected using passive sensing methods from naturalistic smart device use between September 2024 and April 2025. Data were analyzed in May and June 2025.
Main outcome and measures: Adoption rates (ie, number of youth ever accessing GenAI apps on their device) and time spent using GenAI (ie, average minutes accessing GenAI apps), measured by age and time period.
Results: In a cohort of 6488 participants, nearly 2072 youths (31.9%) used GenAI apps on their device. GenAI use was highest among teens (age 13 to 14 years, 899 of 2139 [42.0%]; age 15 to 17 years, 628 of 1246 [50.4%]), although adoption among preteens (age 10 to 12 years, 484 of 2366 [20.5%]) and school-aged children (age 8 to 9 years, 49 of 522 [9.4%]) was not trivial. GenAI usage was higher after school than at nighttime or during school. Overall, users spent a mean (SD) 2.37 (10.55) and a median (IQR) 0.18 (0.04-0.84) minutes a day using GenAI, yet large variances and skewed distributions suggest that a small subset of youth use GenAI extensively, with the heaviest users accessing GenAI for over 40 minutes a day.
Conclusions and relevance: In this cross-sectional study, Gen AI app use varied widely among participants, with up to half of adolescents having some use and a small subset engaging in heavy use. Future research must address individual differences in GenAI use to determine impacts on development.
{"title":"Generative Artificial Intelligence Applications Use Among US Youth.","authors":"Anne J Maheux, Samir Akre-Bhide, Debra Boeldt, Jessica E Flannery, Zachary Richardson, Kaitlyn Burnell, Eva H Telzer, Scott H Kollins","doi":"10.1001/jamanetworkopen.2025.56631","DOIUrl":"10.1001/jamanetworkopen.2025.56631","url":null,"abstract":"<p><strong>Importance: </strong>As generative artificial intelligence (GenAI) tools become increasingly integrated into the daily lives of youth, it is critical to study their usage patterns and potential implications for mental health. While there is evidence of a rapid pace of adoption among adults, rates of GenAI use among youth remains largely undocumented.</p><p><strong>Objective: </strong>To characterize GenAI application (app) usage among US youth, including adoption rates and time spent.</p><p><strong>Design, setting, and participants: </strong>This cross-sectional study documented digital behavior of US youth extracted from a parental monitoring app. Participants were ages 4 to 17 years and were in families using a commercially available Aura app in the US. No identifying information was collected about the child except year of birth. Data were collected using passive sensing methods from naturalistic smart device use between September 2024 and April 2025. Data were analyzed in May and June 2025.</p><p><strong>Main outcome and measures: </strong>Adoption rates (ie, number of youth ever accessing GenAI apps on their device) and time spent using GenAI (ie, average minutes accessing GenAI apps), measured by age and time period.</p><p><strong>Results: </strong>In a cohort of 6488 participants, nearly 2072 youths (31.9%) used GenAI apps on their device. GenAI use was highest among teens (age 13 to 14 years, 899 of 2139 [42.0%]; age 15 to 17 years, 628 of 1246 [50.4%]), although adoption among preteens (age 10 to 12 years, 484 of 2366 [20.5%]) and school-aged children (age 8 to 9 years, 49 of 522 [9.4%]) was not trivial. GenAI usage was higher after school than at nighttime or during school. Overall, users spent a mean (SD) 2.37 (10.55) and a median (IQR) 0.18 (0.04-0.84) minutes a day using GenAI, yet large variances and skewed distributions suggest that a small subset of youth use GenAI extensively, with the heaviest users accessing GenAI for over 40 minutes a day.</p><p><strong>Conclusions and relevance: </strong>In this cross-sectional study, Gen AI app use varied widely among participants, with up to half of adolescents having some use and a small subset engaging in heavy use. Future research must address individual differences in GenAI use to determine impacts on development.</p>","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"9 2","pages":"e2556631"},"PeriodicalIF":9.7,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12865656/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146104792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-02DOI: 10.1001/jamanetworkopen.2025.57332
David Adzrago, Kayo Fujimoto, J Michael Wilkerson, Typhanye V Dyer, Faustine Williams
<p><strong>Importance: </strong>Mental health problems, particularly anxiety and depression, remain among the leading causes of disease burden in the US. However, trends in anxiety and depression across disability status and demographics remain understudied.</p><p><strong>Objective: </strong>To examine trends in anxiety and depression prevalence among US adults from 2019 to 2023 by disability status and demographic characteristics.</p><p><strong>Design, setting, and participants: </strong>This cross-sectional study used national population-based data from the National Health Interview Surveys from 2019 to 2023. Data were collected from household probability samples of noninstitutionalized US civilian adults aged at least 18 years. Data analyses were performed from December 6, 2024, to November 19, 2025.</p><p><strong>Exposures: </strong>Disability status (measured using Washington Group on Disability Statistics Short Set on Functioning), race and ethnicity, sex, and nativity.</p><p><strong>Main outcomes and measures: </strong>The primary outcomes were self-reported anxiety or depression symptoms, assessed using the Washington Group on Disability Statistics Extended Set on Functioning. Joinpoint regression was used to estimate age-standardized prevalence trends and average annual percentage change (AAPC) across disability status, race and ethnicity, sex, and nativity.</p><p><strong>Results: </strong>A total of 150 220 adults were examined (81 525 [51.3%] female; 48 814 individuals [32.3%] aged 45-64 years; 126 051 individuals [81.1%] born in the US), including 16 172 Black individuals (11.9%), 20 427 Hispanic or Latino individuals (17.7%), 12 221 individuals (8.9%) who identified as another race or ethnicity, and 101 400 White individuals (61.4%). There were 15 519 respondents (8.2%) with general disability status and 60 248 respondents (42.3%) with anxiety or depression. From 2019 to 2023, anxiety or depression prevalence increased significantly among individuals without disabilities (AAPC, 3.93; 95% CI, 2.15-5.75). Prevalence increased across all racial and ethnic groups without disabilities, with the highest increases among Black respondents (AAPC, 4.77; 95% CI, 0.61-9.10) and respondents who identified as another race or ethnicity (AAPC, 6.95; 95% CI, 2.56-11.53). Prevalence increased only among females without disabilities (AAPC, 3.50; 95% CI, 2.14-4.87), while increases were observed among males with (AAPC, 3.25; 95% CI, 0.41-6.17) and without (AAPC, 4.62; 95% CI, 1.70-7.63) disabilities. Individuals born outside the US without disabilities experienced higher increases (AAPC, 5.57; 95% CI, 3.10-8.11) than those with disabilities (AAPC, 3.46; 95% CI, 0.06-6.98) and individuals born in the US without disabilities (AAPC, 3.75; 95% CI, 2.14-5.40). Across race and ethnicity, sex, and nativity intersections, Black female individuals born outside the US without disabilities exhibited the highest increase (AAPC, 14.89; 95% CI, 0.48-31.36).</p><p><st
{"title":"Anxiety or Depression Trends by Disability Status and Demographic Intersections in US Adults, 2019-2023.","authors":"David Adzrago, Kayo Fujimoto, J Michael Wilkerson, Typhanye V Dyer, Faustine Williams","doi":"10.1001/jamanetworkopen.2025.57332","DOIUrl":"10.1001/jamanetworkopen.2025.57332","url":null,"abstract":"<p><strong>Importance: </strong>Mental health problems, particularly anxiety and depression, remain among the leading causes of disease burden in the US. However, trends in anxiety and depression across disability status and demographics remain understudied.</p><p><strong>Objective: </strong>To examine trends in anxiety and depression prevalence among US adults from 2019 to 2023 by disability status and demographic characteristics.</p><p><strong>Design, setting, and participants: </strong>This cross-sectional study used national population-based data from the National Health Interview Surveys from 2019 to 2023. Data were collected from household probability samples of noninstitutionalized US civilian adults aged at least 18 years. Data analyses were performed from December 6, 2024, to November 19, 2025.</p><p><strong>Exposures: </strong>Disability status (measured using Washington Group on Disability Statistics Short Set on Functioning), race and ethnicity, sex, and nativity.</p><p><strong>Main outcomes and measures: </strong>The primary outcomes were self-reported anxiety or depression symptoms, assessed using the Washington Group on Disability Statistics Extended Set on Functioning. Joinpoint regression was used to estimate age-standardized prevalence trends and average annual percentage change (AAPC) across disability status, race and ethnicity, sex, and nativity.</p><p><strong>Results: </strong>A total of 150 220 adults were examined (81 525 [51.3%] female; 48 814 individuals [32.3%] aged 45-64 years; 126 051 individuals [81.1%] born in the US), including 16 172 Black individuals (11.9%), 20 427 Hispanic or Latino individuals (17.7%), 12 221 individuals (8.9%) who identified as another race or ethnicity, and 101 400 White individuals (61.4%). There were 15 519 respondents (8.2%) with general disability status and 60 248 respondents (42.3%) with anxiety or depression. From 2019 to 2023, anxiety or depression prevalence increased significantly among individuals without disabilities (AAPC, 3.93; 95% CI, 2.15-5.75). Prevalence increased across all racial and ethnic groups without disabilities, with the highest increases among Black respondents (AAPC, 4.77; 95% CI, 0.61-9.10) and respondents who identified as another race or ethnicity (AAPC, 6.95; 95% CI, 2.56-11.53). Prevalence increased only among females without disabilities (AAPC, 3.50; 95% CI, 2.14-4.87), while increases were observed among males with (AAPC, 3.25; 95% CI, 0.41-6.17) and without (AAPC, 4.62; 95% CI, 1.70-7.63) disabilities. Individuals born outside the US without disabilities experienced higher increases (AAPC, 5.57; 95% CI, 3.10-8.11) than those with disabilities (AAPC, 3.46; 95% CI, 0.06-6.98) and individuals born in the US without disabilities (AAPC, 3.75; 95% CI, 2.14-5.40). Across race and ethnicity, sex, and nativity intersections, Black female individuals born outside the US without disabilities exhibited the highest increase (AAPC, 14.89; 95% CI, 0.48-31.36).</p><p><st","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"9 2","pages":"e2557332"},"PeriodicalIF":9.7,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12865658/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146105626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-02DOI: 10.1001/jamanetworkopen.2025.56867
Haya Kaliounji, Benjamin A Steinberg
{"title":"Institutional Factors and Shared Decision-Making for Atrial Fibrillation.","authors":"Haya Kaliounji, Benjamin A Steinberg","doi":"10.1001/jamanetworkopen.2025.56867","DOIUrl":"https://doi.org/10.1001/jamanetworkopen.2025.56867","url":null,"abstract":"","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"9 2","pages":"e2556867"},"PeriodicalIF":9.7,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146180104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-02DOI: 10.1001/jamanetworkopen.2025.59883
Jennifer N Felder, Daisy León-Martínez, Deborah Karasek, Venise Curry, Kristin Carraway, Patience A Afulani, Bridgette Blebu, Brittany Chambers-Butcher, Kimberly Coleman-Phox, Bethany J Simard, Cinthia Blat, Mary A Garza, Charles E McCulloch, Miriam Kuppermann
<p><strong>Importance: </strong>Racial, ethnic, and income disparities in perinatal depression prevalence and treatment are partially driven by social determinants of health. Effective treatments addressing these determinants are needed.</p><p><strong>Objective: </strong>To determine whether enhanced group prenatal care (eGPC) outperforms enhanced individual prenatal care (eIPC) for reducing perinatal depressive symptoms.</p><p><strong>Design, setting, and participants: </strong>This randomized clinical trial was conduced in 10 Medicaid-serving clinics in California's San Joaquin Valley, enrolling English- or Spanish-speaking Medicaid-eligible pregnant individuals at less than 25 weeks' gestation, from November 2019 to January 2024, with 2 follow-up surveys through 12 weeks postpartum. Analyses were conducted as intention-to-treat. Data were analyzed from December 2024 to December 2025.</p><p><strong>Interventions: </strong>Participants were randomized to eIPC or eGPC. eIPC enhancements included assessments tailored to individual psychosocial, clinical, oral health, and substance use needs. eGPC enhancements included childcare, perinatal mental health screening and referral, transportation stipends, free groceries, and information on community resources.</p><p><strong>Main outcomes and measures: </strong>The primary outcome was depression, operationalized as change in Patient Health Questionnaire-9 scores from baseline to 3 months postpartum. Outcomes were assessed by masked assessors.</p><p><strong>Results: </strong>Of 1663 individuals assessed, 678 were enrolled and randomized; 4 withdrew consent, yielding an analyzed sample of 674 participants (mean [SD] age, 27.0 [5.8] years), including 50 African American or Black participants (7.4%); 37 biracial, multiracial, or multiethnic participants (5.5%); 485 Latine participants (72.0%); 77 White participants (11.4%); and 24 participants who identified as another race or ethnicity (3.6%). After randomization, there were 294 participants in the eGPC group and 380 participants in the eIPC group. No difference in reductions in depressive symptom severity from baseline to 3 months postpartum by randomization group was observed (Cohen d for between-group change, 0.1; 95% CI, -0.1 to 0.3; P = .45), adjusting for baseline depressive symptom severity, self-reported history of a mental health condition, language, and calendar time at enrollment. Instead, participants in both groups experienced small to moderate reductions in depression symptoms from baseline to 3 months postpartum (eGPC: mean [SD] difference, -2.2 [5.3]; Cohen d = -0.4; 95% CI, -0.6 to -0.3; P < .001; eIPC: mean [SD] difference, -1.6 [4.5]; Cohen d = -0.5; 95% CI, -0.6 to -0.4; P < .001).</p><p><strong>Conclusions and relevance: </strong>In this randomized clinical trial of pregnant, low-income, primarily Latine individuals, statistically significant improvements were observed in depressive symptom severity from baseline to postpartum, regardl
重要性:围产期抑郁症患病率和治疗方面的种族、民族和收入差异部分是由健康的社会决定因素驱动的。需要针对这些决定因素的有效治疗。目的:确定加强群体产前护理(eGPC)是否优于加强个人产前护理(eIPC)减轻围产期抑郁症状。设计、环境和参与者:这项随机临床试验在加利福尼亚州圣华金谷的10家医疗补助服务诊所进行,从2019年11月到2024年1月,招募了怀孕不到25周的符合医疗补助条件的英语或西班牙语孕妇,并进行了两次随访调查,直到产后12周。分析作为意向治疗进行。数据分析时间为2024年12月至2025年12月。干预措施:参与者随机分为eIPC组和eGPC组。eIPC的改进包括针对个人心理社会、临床、口腔健康和药物使用需求量身定制的评估。增强的eGPC包括儿童保育、围产期心理健康筛查和转诊、交通补贴、免费食品杂货以及社区资源信息。主要结局和测量:主要结局是抑郁,通过患者健康问卷-9评分从基线到产后3个月的变化来实现。结果由匿名评估者评估。结果:在1663名被评估的个体中,678名被纳入并随机化;4人撤回同意,共分析了674名参与者(平均[SD]年龄27.0[5.8]岁),其中包括50名非裔美国人或黑人参与者(7.4%);37名混血、多种族或多民族参与者(5.5%);拉丁裔参与者485人(72.0%);白人77人(11.4%);24名参与者认为自己是另一个种族或民族(3.6%)。随机分组后,eGPC组有294人,eIPC组有380人。从基线到产后3个月,随机分组在抑郁症状严重程度的减轻方面没有观察到差异(Cohen d组间变化,0.1;95% CI, -0.1 ~ 0.3; P =。45),调整基线抑郁症状严重程度、自我报告的精神健康状况史、语言和入组时的日历时间。相反,从基线到产后3个月,两组参与者的抑郁症状都有小到中度的减轻(eGPC:平均[SD]差异,-2.2 [5.3];Cohen d = -0.4; 95% CI, -0.6至-0.3;P)结论和相关性:在这项针对孕妇、低收入、主要是拉丁裔个体的随机临床试验中,无论产前护理类型如何,从基线到产后,抑郁症状严重程度均有统计学意义的改善。没有证据表明加强产前护理对改善抑郁症状有什么不同。试验注册:ClinicalTrials.gov标识符:NCT04154423。
{"title":"Enhanced Prenatal Care Models and Postpartum Depression: The EMBRACE Randomized Clinical Trial.","authors":"Jennifer N Felder, Daisy León-Martínez, Deborah Karasek, Venise Curry, Kristin Carraway, Patience A Afulani, Bridgette Blebu, Brittany Chambers-Butcher, Kimberly Coleman-Phox, Bethany J Simard, Cinthia Blat, Mary A Garza, Charles E McCulloch, Miriam Kuppermann","doi":"10.1001/jamanetworkopen.2025.59883","DOIUrl":"10.1001/jamanetworkopen.2025.59883","url":null,"abstract":"<p><strong>Importance: </strong>Racial, ethnic, and income disparities in perinatal depression prevalence and treatment are partially driven by social determinants of health. Effective treatments addressing these determinants are needed.</p><p><strong>Objective: </strong>To determine whether enhanced group prenatal care (eGPC) outperforms enhanced individual prenatal care (eIPC) for reducing perinatal depressive symptoms.</p><p><strong>Design, setting, and participants: </strong>This randomized clinical trial was conduced in 10 Medicaid-serving clinics in California's San Joaquin Valley, enrolling English- or Spanish-speaking Medicaid-eligible pregnant individuals at less than 25 weeks' gestation, from November 2019 to January 2024, with 2 follow-up surveys through 12 weeks postpartum. Analyses were conducted as intention-to-treat. Data were analyzed from December 2024 to December 2025.</p><p><strong>Interventions: </strong>Participants were randomized to eIPC or eGPC. eIPC enhancements included assessments tailored to individual psychosocial, clinical, oral health, and substance use needs. eGPC enhancements included childcare, perinatal mental health screening and referral, transportation stipends, free groceries, and information on community resources.</p><p><strong>Main outcomes and measures: </strong>The primary outcome was depression, operationalized as change in Patient Health Questionnaire-9 scores from baseline to 3 months postpartum. Outcomes were assessed by masked assessors.</p><p><strong>Results: </strong>Of 1663 individuals assessed, 678 were enrolled and randomized; 4 withdrew consent, yielding an analyzed sample of 674 participants (mean [SD] age, 27.0 [5.8] years), including 50 African American or Black participants (7.4%); 37 biracial, multiracial, or multiethnic participants (5.5%); 485 Latine participants (72.0%); 77 White participants (11.4%); and 24 participants who identified as another race or ethnicity (3.6%). After randomization, there were 294 participants in the eGPC group and 380 participants in the eIPC group. No difference in reductions in depressive symptom severity from baseline to 3 months postpartum by randomization group was observed (Cohen d for between-group change, 0.1; 95% CI, -0.1 to 0.3; P = .45), adjusting for baseline depressive symptom severity, self-reported history of a mental health condition, language, and calendar time at enrollment. Instead, participants in both groups experienced small to moderate reductions in depression symptoms from baseline to 3 months postpartum (eGPC: mean [SD] difference, -2.2 [5.3]; Cohen d = -0.4; 95% CI, -0.6 to -0.3; P < .001; eIPC: mean [SD] difference, -1.6 [4.5]; Cohen d = -0.5; 95% CI, -0.6 to -0.4; P < .001).</p><p><strong>Conclusions and relevance: </strong>In this randomized clinical trial of pregnant, low-income, primarily Latine individuals, statistically significant improvements were observed in depressive symptom severity from baseline to postpartum, regardl","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"9 2","pages":"e2559883"},"PeriodicalIF":9.7,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12910397/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146201655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-02DOI: 10.1001/jamanetworkopen.2025.58299
Larisa H Cavallari, Rachel A Myers, Hrishikesh Chakraborty, Todd C Skaar, Chancellor F Gray, Jordan F Baye, Simona Volpi, Renee Rider, Emily J Cicali, Erica N Elwood, Elizabeth C Harris, Lindsay J Hines, Noor A Nahid, Khoa A Nguyen, Aniwaa Owusu Obeng, J Andrew Parr, Michelle A Ramos, Lori A Orlando, Hernan A Prieto, Azita Sadeghpour, Rajbir Singh, Petr Starostik, Emma M Tillman, Christina Wyatt, Carol R Horowitz, Deepak Voora, Kathryn V Blake, Hari K Parvataneni, Roger B Fillingim, Paul R Dexter, Josh F Peterson, Julie A Johnson
<p><strong>Importance: </strong>Individuals with genetic variation that results in absent (poor metabolizers) or reduced (intermediate metabolizers) cytochrome P450 2D6 (CYP2D6) enzyme activity have lower concentrations of highly potent active metabolites of tramadol, hydrocodone, and codeine and are thus at increased risk for inadequate pain control.</p><p><strong>Objective: </strong>To determine the effect of CYP2D6-guided opioid prescribing on postoperative pain and opioid use.</p><p><strong>Design, setting, and participants: </strong>This open-label randomized clinical trial enrolled participants from surgery clinics at 8 US health systems. Individuals undergoing a planned surgery anticipated to cause postoperative pain for at least 7 to 10 days were enrolled from March 2021 to September 2023, with follow-up concluded in March 2024.</p><p><strong>Intervention: </strong>Participants in the CYP2D6-guided arm underwent CYP2D6 genotyping before surgery, with recommendations to avoid tramadol, hydrocodone, and codeine for postoperative pain in CYP2D6 poor and intermediate metabolizers, as defined by genotype and use of CYP2D6 inhibitors. Participants in the control arm had usual pain management.</p><p><strong>Main outcomes and measures: </strong>The primary outcome was the 10-day Silverman integrated analgesic assessment (SIA) score, a rank-based composite measure of average pain intensity on a 10-point scale, with higher scores indicating greater pain and opioid use (in morphine milligram equivalents [MMEs]). Secondary end points included individual components of the primary outcome and concordance between metabolizer phenotype and prescribed opioid 10 days after surgery. The primary analysis compared outcomes between poor and intermediate metabolizers in the CYP2D6-guided arm vs the control study arm. The analytical population comprised the subset of intent-to-treat participants with an actionable phenotype who completed surgery.</p><p><strong>Results: </strong>Of 1602 participants enrolled, 351 (mean [SD] age, 62 [13] years; 237 [68%] female) had a CYP2D6 poor or intermediate metabolizer phenotype, proceeded to surgery, and were randomized to the CYP2D6-guided (n = 176) or control (n = 175) study arm. The most common procedures in the actionable population were total knee (177 [50%]) and total hip (97 [28%]) arthroplasties. Concordance between postsurgical opioid treatment and CYP2D6 phenotype was 64% (n = 112) in the CYP2D6-guided arm and 27% (n = 47) in the control arm (difference, 37 [95% CI, 27-46] percentage points; P < .001). At 10 days, the mean (SD) SIA score was 1.4 (95.9) in the CYP2D6-guided arm and -1.4 (93.1) in the control arm (difference, 2.8 [95% CI, -18.3 to 23.8]; P = .80). Mean (SD) numeric pain intensity rating (5.2 [2.2] and 5.1 [2.3]), overall opioid use (13.7 [14.9] and 13.2 [14.7] MME/d), and other secondary end points did not differ between the CYP2D6-guided arm and the control arm.</p><p><strong>Conclusions and relevan
{"title":"CYP2D6-Guided Opioid Management and Postoperative Pain Control: A Randomized Clinical Trial.","authors":"Larisa H Cavallari, Rachel A Myers, Hrishikesh Chakraborty, Todd C Skaar, Chancellor F Gray, Jordan F Baye, Simona Volpi, Renee Rider, Emily J Cicali, Erica N Elwood, Elizabeth C Harris, Lindsay J Hines, Noor A Nahid, Khoa A Nguyen, Aniwaa Owusu Obeng, J Andrew Parr, Michelle A Ramos, Lori A Orlando, Hernan A Prieto, Azita Sadeghpour, Rajbir Singh, Petr Starostik, Emma M Tillman, Christina Wyatt, Carol R Horowitz, Deepak Voora, Kathryn V Blake, Hari K Parvataneni, Roger B Fillingim, Paul R Dexter, Josh F Peterson, Julie A Johnson","doi":"10.1001/jamanetworkopen.2025.58299","DOIUrl":"https://doi.org/10.1001/jamanetworkopen.2025.58299","url":null,"abstract":"<p><strong>Importance: </strong>Individuals with genetic variation that results in absent (poor metabolizers) or reduced (intermediate metabolizers) cytochrome P450 2D6 (CYP2D6) enzyme activity have lower concentrations of highly potent active metabolites of tramadol, hydrocodone, and codeine and are thus at increased risk for inadequate pain control.</p><p><strong>Objective: </strong>To determine the effect of CYP2D6-guided opioid prescribing on postoperative pain and opioid use.</p><p><strong>Design, setting, and participants: </strong>This open-label randomized clinical trial enrolled participants from surgery clinics at 8 US health systems. Individuals undergoing a planned surgery anticipated to cause postoperative pain for at least 7 to 10 days were enrolled from March 2021 to September 2023, with follow-up concluded in March 2024.</p><p><strong>Intervention: </strong>Participants in the CYP2D6-guided arm underwent CYP2D6 genotyping before surgery, with recommendations to avoid tramadol, hydrocodone, and codeine for postoperative pain in CYP2D6 poor and intermediate metabolizers, as defined by genotype and use of CYP2D6 inhibitors. Participants in the control arm had usual pain management.</p><p><strong>Main outcomes and measures: </strong>The primary outcome was the 10-day Silverman integrated analgesic assessment (SIA) score, a rank-based composite measure of average pain intensity on a 10-point scale, with higher scores indicating greater pain and opioid use (in morphine milligram equivalents [MMEs]). Secondary end points included individual components of the primary outcome and concordance between metabolizer phenotype and prescribed opioid 10 days after surgery. The primary analysis compared outcomes between poor and intermediate metabolizers in the CYP2D6-guided arm vs the control study arm. The analytical population comprised the subset of intent-to-treat participants with an actionable phenotype who completed surgery.</p><p><strong>Results: </strong>Of 1602 participants enrolled, 351 (mean [SD] age, 62 [13] years; 237 [68%] female) had a CYP2D6 poor or intermediate metabolizer phenotype, proceeded to surgery, and were randomized to the CYP2D6-guided (n = 176) or control (n = 175) study arm. The most common procedures in the actionable population were total knee (177 [50%]) and total hip (97 [28%]) arthroplasties. Concordance between postsurgical opioid treatment and CYP2D6 phenotype was 64% (n = 112) in the CYP2D6-guided arm and 27% (n = 47) in the control arm (difference, 37 [95% CI, 27-46] percentage points; P < .001). At 10 days, the mean (SD) SIA score was 1.4 (95.9) in the CYP2D6-guided arm and -1.4 (93.1) in the control arm (difference, 2.8 [95% CI, -18.3 to 23.8]; P = .80). Mean (SD) numeric pain intensity rating (5.2 [2.2] and 5.1 [2.3]), overall opioid use (13.7 [14.9] and 13.2 [14.7] MME/d), and other secondary end points did not differ between the CYP2D6-guided arm and the control arm.</p><p><strong>Conclusions and relevan","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"9 2","pages":"e2558299"},"PeriodicalIF":9.7,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146258187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-02DOI: 10.1001/jamanetworkopen.2025.60157
Daisy Thomas, Calvin Diep, Ella Huszti, Juan Pablo Diaz-Martinez, Duminda Wijeysundera, Christopher D Witiw, Blayne A Sayed, Karim S Ladha
Importance: Kidney transplantation improves survival and quality of life for individuals with end-stage kidney disease (ESKD). However, its effect on objective economic outcomes, such as employment income, remains insufficiently studied.
Objective: To quantify changes in employment income before and after kidney transplantation in Canada using linked administrative health and tax data.
Design, setting, and participants: This population-based cohort study included nationwide data from Canadian adults receiving a kidney transplant between 2007 and 2016. Data were from the Canadian Hospitalization and Taxation Database (C-HAT), which includes hospital discharge records and income tax data. Eligible adults were aged 30 to 62 years; exclusions included repeat or multiorgan transplants, residents of Quebec or territories, and individuals with incomplete tax data or those in the top or bottom 1% of income earners. Data analyses were conducted between June 2024 to October 2025.
Exposure: Kidney transplant.
Main outcome and measures: The primary outcome was annual employment income, derived from tax records for 3 years before and after transplant. Employment income was defined as the combined total of employment income, self-employment income, and other employment income, and adjusted to 2023 Canadian dollars using the Bank of Canada Consumer Price Index. A linear mixed-effects model was used to evaluate changes in income over time.
Results: The final cohort included 3230 individuals (mean [SD] age, 47 [8.4] years), of whom 1120 (34.7%) were female and 2630 (81.4%) were aged 30 to 55 years. Pretransplant, income declined by $4293 per year (95% CI, -$4726 to -$3861 per year; P < .001); posttransplant, income increased by $1006 per year (95% CI, $406 to $1605; P = .001).
Conclusions and relevance: In this cohort study of 3230 kidney transplant recipients, kidney transplant was associated with a reversal of declining employment income, indicating meaningful economic recovery. These findings highlight the broader socioeconomic value of transplantation and may inform policies that support patients during pretransplant vulnerability and facilitate successful return to work.
{"title":"Transplantation and Employment Earnings in Kidney Transplant Recipients.","authors":"Daisy Thomas, Calvin Diep, Ella Huszti, Juan Pablo Diaz-Martinez, Duminda Wijeysundera, Christopher D Witiw, Blayne A Sayed, Karim S Ladha","doi":"10.1001/jamanetworkopen.2025.60157","DOIUrl":"https://doi.org/10.1001/jamanetworkopen.2025.60157","url":null,"abstract":"<p><strong>Importance: </strong>Kidney transplantation improves survival and quality of life for individuals with end-stage kidney disease (ESKD). However, its effect on objective economic outcomes, such as employment income, remains insufficiently studied.</p><p><strong>Objective: </strong>To quantify changes in employment income before and after kidney transplantation in Canada using linked administrative health and tax data.</p><p><strong>Design, setting, and participants: </strong>This population-based cohort study included nationwide data from Canadian adults receiving a kidney transplant between 2007 and 2016. Data were from the Canadian Hospitalization and Taxation Database (C-HAT), which includes hospital discharge records and income tax data. Eligible adults were aged 30 to 62 years; exclusions included repeat or multiorgan transplants, residents of Quebec or territories, and individuals with incomplete tax data or those in the top or bottom 1% of income earners. Data analyses were conducted between June 2024 to October 2025.</p><p><strong>Exposure: </strong>Kidney transplant.</p><p><strong>Main outcome and measures: </strong>The primary outcome was annual employment income, derived from tax records for 3 years before and after transplant. Employment income was defined as the combined total of employment income, self-employment income, and other employment income, and adjusted to 2023 Canadian dollars using the Bank of Canada Consumer Price Index. A linear mixed-effects model was used to evaluate changes in income over time.</p><p><strong>Results: </strong>The final cohort included 3230 individuals (mean [SD] age, 47 [8.4] years), of whom 1120 (34.7%) were female and 2630 (81.4%) were aged 30 to 55 years. Pretransplant, income declined by $4293 per year (95% CI, -$4726 to -$3861 per year; P < .001); posttransplant, income increased by $1006 per year (95% CI, $406 to $1605; P = .001).</p><p><strong>Conclusions and relevance: </strong>In this cohort study of 3230 kidney transplant recipients, kidney transplant was associated with a reversal of declining employment income, indicating meaningful economic recovery. These findings highlight the broader socioeconomic value of transplantation and may inform policies that support patients during pretransplant vulnerability and facilitate successful return to work.</p>","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"9 2","pages":"e2560157"},"PeriodicalIF":9.7,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146226430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-02DOI: 10.1001/jamanetworkopen.2025.59940
Jonathan Staloff, Eric Gunnink, Jorge Rojas, Edwin S Wong, Jacqueline M Ferguson, Donna M Zulman, Karin Nelson, Ashok Reddy
Importance: As telehealth (ie, telephone and video) becomes a larger component of primary care, understanding its impact on care quality is critical.
Objective: To evaluate whether the proportion of primary care received via telehealth is associated with differences in quality-of-care outcomes among veterans who frequently use primary care.
Design, setting, and participants: This is a retrospective cohort study of veterans empaneled to Veterans Health Administration (VHA) primary care in fiscal years 2022 and 2023 (October 1, 2021, to September 30, 2023) with 3 or more primary care visits. Telehealth proportion categories were none (0.0% primary care visits telehealth), low (>0.0% to <28.6%), intermediate (28.6% to <50.0%), or high (≥50.0%).
Exposure: Proportion of primary care delivered via telehealth.
Main outcomes and measures: The primary outcomes were influenza vaccination, hypertension control, statin therapy and adherence, and screenings and/or counseling for depression, tobacco, and alcohol use. Multivariable logistic regression was used to estimate adjusted average marginal effects (AMEs), controlling for sociodemographic, geographic, and clinical characteristics.
Results: This study included 744 599 veterans (mean [SD] age, 65 [15] years; 638 289 male [86%]). Compared with veterans receiving in-person care only, those who received a low proportion of care via telehealth had similar quality of outcomes for all cardiovascular and behavioral health measures. Influenza vaccination rates were modestly lower in the low-telehealth group vs the in-person only group (age ≥66 years, AME, -1.93% [95% CI, -2.58% to -1.29%]; age 19-65 years, AME, -1.57% [95% CI, -2.28% to -0.86%]). High telehealth users (≥50% telehealth) had the lowest adjusted likelihoods for most quality outcomes, including influenza vaccination (age ≥66 years, AME, -8.96% [95% CI, -9.84% to -8.07%]; age 19-65 years, AME, -9.72% [95% CI, -10.84% to -8.60%]) statin adherence (AME, -2.03% [95% CI -2.93% to -1.14%]) and depression screening (AME, -2.14% [95% CI, -3.20% to -1.08%]).
Conclusions and relevance: In this cohort study of veterans with 3 or more primary care visits, primary care quality was similar for individuals who received all in-person care and those receiving low or intermediate proportions of telehealth. However, high telehealth use was associated with lower quality for several services, especially those requiring in-person interaction. Findings demonstrate the viability of hybrid telehealth and in-person models. Additional resources might be needed to ensure high-quality primary care for high proportion telehealth users.
{"title":"Primary Care by Telehealth and Care Quality in the Veterans Health Administration.","authors":"Jonathan Staloff, Eric Gunnink, Jorge Rojas, Edwin S Wong, Jacqueline M Ferguson, Donna M Zulman, Karin Nelson, Ashok Reddy","doi":"10.1001/jamanetworkopen.2025.59940","DOIUrl":"10.1001/jamanetworkopen.2025.59940","url":null,"abstract":"<p><strong>Importance: </strong>As telehealth (ie, telephone and video) becomes a larger component of primary care, understanding its impact on care quality is critical.</p><p><strong>Objective: </strong>To evaluate whether the proportion of primary care received via telehealth is associated with differences in quality-of-care outcomes among veterans who frequently use primary care.</p><p><strong>Design, setting, and participants: </strong>This is a retrospective cohort study of veterans empaneled to Veterans Health Administration (VHA) primary care in fiscal years 2022 and 2023 (October 1, 2021, to September 30, 2023) with 3 or more primary care visits. Telehealth proportion categories were none (0.0% primary care visits telehealth), low (>0.0% to <28.6%), intermediate (28.6% to <50.0%), or high (≥50.0%).</p><p><strong>Exposure: </strong>Proportion of primary care delivered via telehealth.</p><p><strong>Main outcomes and measures: </strong>The primary outcomes were influenza vaccination, hypertension control, statin therapy and adherence, and screenings and/or counseling for depression, tobacco, and alcohol use. Multivariable logistic regression was used to estimate adjusted average marginal effects (AMEs), controlling for sociodemographic, geographic, and clinical characteristics.</p><p><strong>Results: </strong>This study included 744 599 veterans (mean [SD] age, 65 [15] years; 638 289 male [86%]). Compared with veterans receiving in-person care only, those who received a low proportion of care via telehealth had similar quality of outcomes for all cardiovascular and behavioral health measures. Influenza vaccination rates were modestly lower in the low-telehealth group vs the in-person only group (age ≥66 years, AME, -1.93% [95% CI, -2.58% to -1.29%]; age 19-65 years, AME, -1.57% [95% CI, -2.28% to -0.86%]). High telehealth users (≥50% telehealth) had the lowest adjusted likelihoods for most quality outcomes, including influenza vaccination (age ≥66 years, AME, -8.96% [95% CI, -9.84% to -8.07%]; age 19-65 years, AME, -9.72% [95% CI, -10.84% to -8.60%]) statin adherence (AME, -2.03% [95% CI -2.93% to -1.14%]) and depression screening (AME, -2.14% [95% CI, -3.20% to -1.08%]).</p><p><strong>Conclusions and relevance: </strong>In this cohort study of veterans with 3 or more primary care visits, primary care quality was similar for individuals who received all in-person care and those receiving low or intermediate proportions of telehealth. However, high telehealth use was associated with lower quality for several services, especially those requiring in-person interaction. Findings demonstrate the viability of hybrid telehealth and in-person models. Additional resources might be needed to ensure high-quality primary care for high proportion telehealth users.</p>","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"9 2","pages":"e2559940"},"PeriodicalIF":9.7,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12914489/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146213049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-02DOI: 10.1001/jamanetworkopen.2025.59998
Hilla Pöyry, Jenni Turunen, Elisa Ritola, Sofia Hartikainen, Joni Palviainen, Ilona Liimatta, Ulla Koskela, Tytti Pokka, Marjo Renko, Niko Paalanne, Otto Helve, Mysore V Tejesvi, Terhi Ruuska-Loewald
Importance: Early parental recognition of severe illness in children and adolescents is crucial for timely management and improved outcomes in pediatric emergency care.
Objective: To assess how accurately parents can identify severe illness in their children using a questionnaire completed shortly after arrival at the emergency department (ED).
Design, setting, and participants: This diagnostic study was conducted in a tertiary pediatric ED in northern Finland. Data were collected in 2019 to 2021, and this analysis was conducted in May 2024 to May 2025. Children and adolescents whose parents completed the questionnaire before physician assessment were included.
Exposures: A structured, 36-item parental questionnaire assessing symptoms and the child or adolescent's overall condition.
Main outcomes and measures: Severe illness was defined as 1 or more of the following: admission to the pediatric intensive care unit, hospital treatment of more than 24 hours, need for intravenous or nasogastric fluids, need for intravenous antibiotics for more than 24 hours, oxygen saturation less than 93% or the need for inhaled medications, anaphylactic shock, intoxication requiring hospital admission, or surgical intervention. Sensitivity and specificity were calculated for each question. To identify parental triage questions with the strongest diagnostic value, a machine learning analysis was conducted.
Results: Among 2375 included children and adolescents (mean [SD] age, 5.4 [4.6] years; 1140 female [48.0%]), 567 individuals (23.9%) met criteria for severe illness. Moderate to high parental worry showed the highest sensitivity (91.0% [95% CI, 88.3%-93.2%]) but the lowest specificity (17.5% [95% CI, 15.8%-19.4%]). Other specific pediatric questions demonstrated modest diagnostic accuracy with limited additional value. The machine learning model (area under the receiver operating characteristic curve, 0.71; 95% CI, 0.65-0.77) identified parental worry (feature importance score, 0.047), parent assessments of child or adolescent's general condition (feature importance score, 0.046), and need for treatment (feature importance score, 0.141) as the strongest predictors of hospital admission.
Conclusions and relevance: In this study, parental worry identified most cases of severe illness but had low specificity. These findings suggest that while parental concern may serve as an initial screening indicator, it should be complemented by clinical evaluation and objective measures to avoid unnecessary escalation of care.
{"title":"Parental Ability to Identify Severe Illnesses in Their Children.","authors":"Hilla Pöyry, Jenni Turunen, Elisa Ritola, Sofia Hartikainen, Joni Palviainen, Ilona Liimatta, Ulla Koskela, Tytti Pokka, Marjo Renko, Niko Paalanne, Otto Helve, Mysore V Tejesvi, Terhi Ruuska-Loewald","doi":"10.1001/jamanetworkopen.2025.59998","DOIUrl":"10.1001/jamanetworkopen.2025.59998","url":null,"abstract":"<p><strong>Importance: </strong>Early parental recognition of severe illness in children and adolescents is crucial for timely management and improved outcomes in pediatric emergency care.</p><p><strong>Objective: </strong>To assess how accurately parents can identify severe illness in their children using a questionnaire completed shortly after arrival at the emergency department (ED).</p><p><strong>Design, setting, and participants: </strong>This diagnostic study was conducted in a tertiary pediatric ED in northern Finland. Data were collected in 2019 to 2021, and this analysis was conducted in May 2024 to May 2025. Children and adolescents whose parents completed the questionnaire before physician assessment were included.</p><p><strong>Exposures: </strong>A structured, 36-item parental questionnaire assessing symptoms and the child or adolescent's overall condition.</p><p><strong>Main outcomes and measures: </strong>Severe illness was defined as 1 or more of the following: admission to the pediatric intensive care unit, hospital treatment of more than 24 hours, need for intravenous or nasogastric fluids, need for intravenous antibiotics for more than 24 hours, oxygen saturation less than 93% or the need for inhaled medications, anaphylactic shock, intoxication requiring hospital admission, or surgical intervention. Sensitivity and specificity were calculated for each question. To identify parental triage questions with the strongest diagnostic value, a machine learning analysis was conducted.</p><p><strong>Results: </strong>Among 2375 included children and adolescents (mean [SD] age, 5.4 [4.6] years; 1140 female [48.0%]), 567 individuals (23.9%) met criteria for severe illness. Moderate to high parental worry showed the highest sensitivity (91.0% [95% CI, 88.3%-93.2%]) but the lowest specificity (17.5% [95% CI, 15.8%-19.4%]). Other specific pediatric questions demonstrated modest diagnostic accuracy with limited additional value. The machine learning model (area under the receiver operating characteristic curve, 0.71; 95% CI, 0.65-0.77) identified parental worry (feature importance score, 0.047), parent assessments of child or adolescent's general condition (feature importance score, 0.046), and need for treatment (feature importance score, 0.141) as the strongest predictors of hospital admission.</p><p><strong>Conclusions and relevance: </strong>In this study, parental worry identified most cases of severe illness but had low specificity. These findings suggest that while parental concern may serve as an initial screening indicator, it should be complemented by clinical evaluation and objective measures to avoid unnecessary escalation of care.</p>","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"9 2","pages":"e2559998"},"PeriodicalIF":9.7,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12914493/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146213097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-02DOI: 10.1001/jamanetworkopen.2025.59892
Lauren E Russell, David A Frank, Soumik Purkayastha, Jennifer L McCoy, Sarah M Leder, Joshua H Gordon, Shane Lamba, Gregory T Procario, Ernest M Moy, Leslie R M Hausmann
<p><strong>Importance: </strong>Social screening initiatives often prioritize identifying social risks before offering support. The extent to which the emphasis on social risks contribute to overscreening and/or underdetection of needs, overall and across demographic subgroups, remains underexplored.</p><p><strong>Objective: </strong>To examine the agreement between self-reported social risks and needs for support and variance in risk-need concordance across racial, ethnic, and sex subgroups.</p><p><strong>Design, setting, and participants: </strong>This cross-sectional study examined responses to an online or mailed survey fielded between March 2 and May 9, 2023, to Veterans Health Administration patients who visited their primary care practitioner in January or February 2023. Survey weights were used to adjust for sampling frame and nonresponse. The data were analyzed between April 6 and December 15, 2025.</p><p><strong>Exposure: </strong>Intersection of race, ethnicity, and sex.</p><p><strong>Main outcomes and measures: </strong>Risk-need sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and concordance across 12 domains (paying for basics, obtaining adult caregiving, obtaining childcare, finding or keeping work, paying for food, finding or keeping housing, getting transportation, accessing the internet at home, feeling isolated, feeling lonely, getting legal assistance, and getting additional education or job training) were measured using age-adjusted relative risk ratios (ARRRs) of risk-need discordance (vs concordance), controlling for a family-wise error rate of .05.</p><p><strong>Results: </strong>The analytic sample included 6596 respondents, representing 937 003 veterans after weighting (unweighted number [weighted percentage]: aged <65 years, 2992 [48.5%]; aged ≥65 years, 3604 [51.5%]; 1088 identifying as Black female [4.1%], 1140 as Black male [19.4%], 939 as Hispanic female [1.6%], 1279 as Hispanic male [11.3%], 802 as White female [5.3%], and 1348 as White male [58.4%] race or ethnicity and sex). Across domains, risk-need sensitivity ranged from 42% (95% CI, 34%-49%) for housing to 99% (95% CI, 98%-99%) for loneliness, and specificity ranged from 69% (95% CI, 66%-71%) for loneliness to 98% (95% CI, 97%-99%) for childcare. The PPV ranged from 27% (95% CI, 22%-33%) for housing to 69% (95% CI, 63%-75%) for legal issues, and NPV ranged from 93% (95% CI, 91%-94%) for housing to 99% (95% CI, 99%-99%) for both childcare and loneliness. In age-adjusted models, compared with White male veterans, Black male veterans had a significantly higher likelihood of need-without-risk discordance for paying for basics (ARRR, 3.95; 95% CI, 1.80-8.64), housing (ARRR, 2.67; 95% CI, 1.59-4.48), and adult caregiving (ARRR, 2.13; 95% CI, 1.30-3.48). Additionally, compared with White male veterans, the likelihood of need-without-risk discordance for loneliness was higher among White female (ARRR, 14.02; 95% CI, 2.85-68
{"title":"Racial, Ethnic, and Sex Differences in Social Risks and Social Needs Concordance Among Veterans.","authors":"Lauren E Russell, David A Frank, Soumik Purkayastha, Jennifer L McCoy, Sarah M Leder, Joshua H Gordon, Shane Lamba, Gregory T Procario, Ernest M Moy, Leslie R M Hausmann","doi":"10.1001/jamanetworkopen.2025.59892","DOIUrl":"10.1001/jamanetworkopen.2025.59892","url":null,"abstract":"<p><strong>Importance: </strong>Social screening initiatives often prioritize identifying social risks before offering support. The extent to which the emphasis on social risks contribute to overscreening and/or underdetection of needs, overall and across demographic subgroups, remains underexplored.</p><p><strong>Objective: </strong>To examine the agreement between self-reported social risks and needs for support and variance in risk-need concordance across racial, ethnic, and sex subgroups.</p><p><strong>Design, setting, and participants: </strong>This cross-sectional study examined responses to an online or mailed survey fielded between March 2 and May 9, 2023, to Veterans Health Administration patients who visited their primary care practitioner in January or February 2023. Survey weights were used to adjust for sampling frame and nonresponse. The data were analyzed between April 6 and December 15, 2025.</p><p><strong>Exposure: </strong>Intersection of race, ethnicity, and sex.</p><p><strong>Main outcomes and measures: </strong>Risk-need sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and concordance across 12 domains (paying for basics, obtaining adult caregiving, obtaining childcare, finding or keeping work, paying for food, finding or keeping housing, getting transportation, accessing the internet at home, feeling isolated, feeling lonely, getting legal assistance, and getting additional education or job training) were measured using age-adjusted relative risk ratios (ARRRs) of risk-need discordance (vs concordance), controlling for a family-wise error rate of .05.</p><p><strong>Results: </strong>The analytic sample included 6596 respondents, representing 937 003 veterans after weighting (unweighted number [weighted percentage]: aged <65 years, 2992 [48.5%]; aged ≥65 years, 3604 [51.5%]; 1088 identifying as Black female [4.1%], 1140 as Black male [19.4%], 939 as Hispanic female [1.6%], 1279 as Hispanic male [11.3%], 802 as White female [5.3%], and 1348 as White male [58.4%] race or ethnicity and sex). Across domains, risk-need sensitivity ranged from 42% (95% CI, 34%-49%) for housing to 99% (95% CI, 98%-99%) for loneliness, and specificity ranged from 69% (95% CI, 66%-71%) for loneliness to 98% (95% CI, 97%-99%) for childcare. The PPV ranged from 27% (95% CI, 22%-33%) for housing to 69% (95% CI, 63%-75%) for legal issues, and NPV ranged from 93% (95% CI, 91%-94%) for housing to 99% (95% CI, 99%-99%) for both childcare and loneliness. In age-adjusted models, compared with White male veterans, Black male veterans had a significantly higher likelihood of need-without-risk discordance for paying for basics (ARRR, 3.95; 95% CI, 1.80-8.64), housing (ARRR, 2.67; 95% CI, 1.59-4.48), and adult caregiving (ARRR, 2.13; 95% CI, 1.30-3.48). Additionally, compared with White male veterans, the likelihood of need-without-risk discordance for loneliness was higher among White female (ARRR, 14.02; 95% CI, 2.85-68","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"9 2","pages":"e2559892"},"PeriodicalIF":9.7,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12914491/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146213120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-02DOI: 10.1001/jamanetworkopen.2025.59946
Lisa K Gilliam, Melissa M Parker, Minnie W Chen, Andrew J Karter, Richard W Grant
<p><strong>Importance: </strong>Severe hypoglycemia is a life-threatening, iatrogenic complication of diabetes medications associated with increased risks of falls, cardiovascular events, cognitive decline, and mortality.</p><p><strong>Objective: </strong>To determine whether proactive outreach by a clinical pharmacist applying an evidence-based hypoglycemia-prevention algorithm (Hypoglycemia on a Page) would result in safer prescribing of diabetes regimens among patients with type 2 diabetes (T2D) with hypoglycemia risk.</p><p><strong>Design, setting, and participants: </strong>This randomized clinical trial was conducted between July 20, 2023, and January 22, 2024, with follow-up outcomes collected through January 2025. The study included adults with T2D at high risk of hypoglycemia based on a validated hypoglycemia risk tool. The trial was conducted within Kaiser Permanente Northern California, a large, integrated health care delivery system.</p><p><strong>Intervention: </strong>Patients were randomized 1:1 to either a protocol-driven outreach by a clinical pharmacist (intervention) arm or a usual care (control) arm.</p><p><strong>Main outcome and measure: </strong>The main outcome was the comparison of the proportion of patients who were prescribed safer (less hypoglycemia-prone) diabetes regimens, defined as discontinuation of sulfonylureas and/or rapid-acting or short-acting or mixed insulins, using an intention-to-treat analysis.</p><p><strong>Results: </strong>From an eligible population of 1204 patients, 200 were enrolled into the clinical trial. Among these, 191 patients were in the intention-to-treat cohort (mean [SD] age, 71.3 [11.5] years; 100 females [52.4%]). The 2 study arms were similar at baseline in terms of race and ethnicity, sex, mean (SD) hemoglobin A1c (HbA1c) level (intervention: 8.0 [1.3]; control: 8.3 [1.8]), and number (percentage) of patients receiving insulin (intervention: 82 [85.4%]; control:85 [89.5%]) and sulfonylurea (intervention: 25 [26.0%]; control: 21 [22.1%]). At 6 months, patients in the intervention arm were more likely to be prescribed a safer diabetes regimen than those in the control arm (27 [28.1%] vs 15 [15.8%]; risk difference [RD], 12.3% [95% CI, 0.6% to 24.0%]). Patients in the intervention arm also experienced significantly fewer hypoglycemia-related emergency department or inpatient encounters (0 vs 5 [5.3%]; RD, -5.3% [95% CI, -11.8% to -1.3%]). There was no worsening of HbA1c control in the intervention arm compared with the control arm (47 [61.8%] vs 49 [63.6%] with HbA1c <8%; RD, -1.8% [95% CI, -17.0% to 13.5%]).</p><p><strong>Conclusions and relevance: </strong>In this randomized clinical trial, adding proactive, protocol-driven clinical pharmacist outreach into collaborative team-based care improved medication optimization and patient outcomes. This approach provides an evidence-based strategy for reducing the risk of developing severe hypoglycemia in individuals with T2D at high risk, enh
重要性:严重低血糖是一种危及生命的医源性糖尿病药物并发症,与跌倒、心血管事件、认知能力下降和死亡率的风险增加有关。目的:确定临床药师应用循证低血糖预防算法(Hypoglycemia on a Page)的主动外展是否会使有低血糖风险的2型糖尿病(T2D)患者更安全地开具糖尿病方案处方。设计、环境和参与者:该随机临床试验于2023年7月20日至2024年1月22日进行,随访结果收集至2025年1月。该研究基于有效的低血糖风险工具纳入了低血糖高风险的t2dm成人。该试验是在北加州凯撒医疗机构进行的,这是一个大型的综合医疗服务系统。干预:患者按1:1随机分为临床药师(干预)组或常规护理(对照)组。主要结局和测量:主要结局是比较使用意向治疗分析的更安全(低血糖倾向较少)糖尿病方案(定义为停用磺脲类药物和/或速效或短效或混合胰岛素)的患者比例。结果:从符合条件的1204例患者中,有200例入组临床试验。其中意向治疗队列191例(平均[SD]年龄71.3[11.5]岁,女性100例[52.4%])。两个研究组在基线时的种族、民族、性别、平均(SD)血红蛋白A1c (HbA1c)水平(干预组:8.0[1.3];对照组:8.3[1.8])和接受胰岛素(干预组:82[85.4%];对照组:85[89.5%])和磺脲类药物(干预组:25[26.0%];对照组:21[22.1%])的患者数量(百分比)相似。6个月时,干预组患者比对照组患者更有可能得到更安全的糖尿病治疗方案(27例[28.1%]vs 15例[15.8%];风险差异[RD], 12.3% [95% CI, 0.6%至24.0%])。干预组患者与低血糖相关的急诊或住院经历也显著减少(0比5 [5.3%];RD, -5.3% [95% CI, -11.8%至-1.3%])。与对照组相比,干预组的HbA1c控制没有恶化(47例[61.8%]vs 49例[63.6%])。结论和相关性:在这项随机临床试验中,在协作式团队护理中加入积极的、协议驱动的临床药师外展,改善了药物优化和患者预后。该方法提供了一种基于证据的策略,可降低高危T2D患者发生严重低血糖的风险,增强患者安全,并有可能降低总体医疗成本。试验注册:ClinicalTrials.gov标识符:NCT06746714。
{"title":"Pharmacist Intervention for Safer Prescribing in Patients With Type 2 Diabetes at High Risk: A Randomized Clinical Trial.","authors":"Lisa K Gilliam, Melissa M Parker, Minnie W Chen, Andrew J Karter, Richard W Grant","doi":"10.1001/jamanetworkopen.2025.59946","DOIUrl":"10.1001/jamanetworkopen.2025.59946","url":null,"abstract":"<p><strong>Importance: </strong>Severe hypoglycemia is a life-threatening, iatrogenic complication of diabetes medications associated with increased risks of falls, cardiovascular events, cognitive decline, and mortality.</p><p><strong>Objective: </strong>To determine whether proactive outreach by a clinical pharmacist applying an evidence-based hypoglycemia-prevention algorithm (Hypoglycemia on a Page) would result in safer prescribing of diabetes regimens among patients with type 2 diabetes (T2D) with hypoglycemia risk.</p><p><strong>Design, setting, and participants: </strong>This randomized clinical trial was conducted between July 20, 2023, and January 22, 2024, with follow-up outcomes collected through January 2025. The study included adults with T2D at high risk of hypoglycemia based on a validated hypoglycemia risk tool. The trial was conducted within Kaiser Permanente Northern California, a large, integrated health care delivery system.</p><p><strong>Intervention: </strong>Patients were randomized 1:1 to either a protocol-driven outreach by a clinical pharmacist (intervention) arm or a usual care (control) arm.</p><p><strong>Main outcome and measure: </strong>The main outcome was the comparison of the proportion of patients who were prescribed safer (less hypoglycemia-prone) diabetes regimens, defined as discontinuation of sulfonylureas and/or rapid-acting or short-acting or mixed insulins, using an intention-to-treat analysis.</p><p><strong>Results: </strong>From an eligible population of 1204 patients, 200 were enrolled into the clinical trial. Among these, 191 patients were in the intention-to-treat cohort (mean [SD] age, 71.3 [11.5] years; 100 females [52.4%]). The 2 study arms were similar at baseline in terms of race and ethnicity, sex, mean (SD) hemoglobin A1c (HbA1c) level (intervention: 8.0 [1.3]; control: 8.3 [1.8]), and number (percentage) of patients receiving insulin (intervention: 82 [85.4%]; control:85 [89.5%]) and sulfonylurea (intervention: 25 [26.0%]; control: 21 [22.1%]). At 6 months, patients in the intervention arm were more likely to be prescribed a safer diabetes regimen than those in the control arm (27 [28.1%] vs 15 [15.8%]; risk difference [RD], 12.3% [95% CI, 0.6% to 24.0%]). Patients in the intervention arm also experienced significantly fewer hypoglycemia-related emergency department or inpatient encounters (0 vs 5 [5.3%]; RD, -5.3% [95% CI, -11.8% to -1.3%]). There was no worsening of HbA1c control in the intervention arm compared with the control arm (47 [61.8%] vs 49 [63.6%] with HbA1c <8%; RD, -1.8% [95% CI, -17.0% to 13.5%]).</p><p><strong>Conclusions and relevance: </strong>In this randomized clinical trial, adding proactive, protocol-driven clinical pharmacist outreach into collaborative team-based care improved medication optimization and patient outcomes. This approach provides an evidence-based strategy for reducing the risk of developing severe hypoglycemia in individuals with T2D at high risk, enh","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"9 2","pages":"e2559946"},"PeriodicalIF":9.7,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12917679/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146219962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}